This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

ClinicalRM Awarded NIH Contract To Support The STI CTG Program

FREDERICK, Md., Sept. 11, 2013 /PRNewswire/ -- Clinical Research Management, Inc. (ClinicalRM) – a full-service Contract Research Organization (CRO) providing services for basic and applied research, clinical trials, and regulatory support – announced today it was awarded a contract by the Department of Health and Human Services, National Institutes of Health, Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID). The intent of the award is to provide a broad spectrum of services for the design and conduct of Phase I-IV clinical trials and clinical studies focused on the screening, diagnosis, treatment, prevention, and control of Sexually Transmitted Infections within the Sexually Transmitted Infections Clinical Trials Group (STI CTG) Program.

ClinicalRM has partnered with Johns Hopkins University (JHU) and is one of only three other companies to be awarded this contract. 100% of the total costs of the program will be financed with Federal money.  The contract ceiling for the 7-year STI CTG Program for all awardees is $70 M. The STI CTG contract is an Indefinite Delivery/Indefinite Quantity (ID/IQ) contract.

"This award gives us an opportunity to test the effectiveness of several new - and older - medications to treat and prevent STIs," said Dr. Mac Griffiss, Principal Investigator on the contract. "It comes at a time when many of the causes of these infections are becoming increasingly resistant to current antibiotics. We have protocols that are ready to be implemented, and we are excited at the prospect of improving the outcome of these infections."

Dr. Jonathan Zenilman, a Central Investigator on the contract from JHU, stated, "The recent STI contract award builds tremendously on our groups' experience and strengths.  ClinicalRM, Case Western Reserve University, and JHU have been enormously successful in the Phase I infectious disease programs.  The STI CTG allows us to integrate our clinical expertise in STI/HIV research and provide a seamless Phase I-III path for new STI treatments."

The mission of the Program is to foster, develop, and administer a research program that will contribute to human reproductive health and specifically lead to the prevention and control of STIs. The broad public health goals of this research program focus on the prevention of (i) STIs and associated syndromes; (ii) infertility; (iii) adverse outcomes of pregnancy, including preterm birth and low birth weight; (iv) reproductive tract neoplasia; and (v) other chronic STI sequelae. Victoria Tifft, CEO of ClinicalRM, stated, "ClinicalRM is proud to engage in this critical work with NIAID and JHU. The award of this contract allows us to continue to build strong and meaningful partnerships with the Government, industry, and academia to combat a variety of infectious diseases."

About the NIAIDThe NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world.

About ClinicalRMFounded in 1994, ClinicalRM is a full-service CRO specializing in preclinical and Phase I-IV clinical research, clinical trial support, and product development for biologics, drugs, and devices. ClinicalRM prides itself on providing outstanding customer service and exceeding client expectations. For more information, please go to

Contact: Rachel Fleshman,, 1-800-431-9640 x218 


Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs